Wire · operational-macro
uniQure Announces FDA Acceptance and Priority Review of the Biologics License ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
uniQure's gene therapy ifezuntirgene inilparvovec for Huntington’s disease has received FDA acceptance for Biologics License Application review with Priority Review status and a PDUFA action date of May 1, 2027, potentially becoming the first disease-modifying treatment for the condition.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 2 Nov 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
The FDA's priority review opens a fast track to market for gene therapy in Huntington's disease, positioning you to focus on clinical validation while preparing for launch. Your development timeline tightens as the industry eyes the first approved disease-modifying treatment in this area.
◆ Coverage
3 sources · first reported 2 Nov 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics